Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared with Originator Insulin Glargine (Lantus®) in Patients with Type 1 Diabetes after 26 Weeks Treatment.
Christofides EA, Stankiewicz A, Denham D, Bellido D, Franek E, Nakhle S, Łukaszewicz M, Reed J, Cózar-León V, Kosch C, Karaś P, Fitz-Patrick D, Handelsman Y, Warren M, Hollander P, Huffman D, Raskin P, Oroszlán T, Lillestol M, Ovalle F.
Christofides EA, et al. Among authors: hollander p.
Endocr Pract. 2024 Jun 12:S1530-891X(24)00553-6. doi: 10.1016/j.eprac.2024.06.002. Online ahead of print.
Endocr Pract. 2024.
PMID: 38876181